The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Tumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD)....

Descripción completa

Detalles Bibliográficos
Autores principales: Sottotetti, Federico, Ferraris, Elisa, Tagliaferri, Barbara, Palumbo, Raffaella, Quaquarini, Erica, Teragni, Cristina, Balletti, Emanuela, Leli, Claudia, Premoli, Andrea, Mollica, Ludovica, Puglisi, Silvia, Sardi, Silvia, Malovini, Alberto, Pedrazzoli, Paolo, Bernardo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451191/
https://www.ncbi.nlm.nih.gov/pubmed/36118250
http://dx.doi.org/10.7573/dic.2022-1-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451191/
https://www.ncbi.nlm.nih.gov/pubmed/36118250
http://dx.doi.org/10.7573/dic.2022-1-3

Ejemplares similares